AMSTERDAM — The Janus kinase inhibitor delgocitinib may be a better or comparable choice for treating hand eczema than some more established therapies, suggested the results of two separate studies ...
The evaluation committee considered evidence submitted by Leo Pharma, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback